Letter

Fluoroquinolone resistance in Salmonella Typhi

BMJ 2006; 333 doi: 10.1136/bmj.333.7563.353-b (Published 10 August 2006)
Cite this as: BMJ 2006;333:353.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Fiona J Cooke (fiona@sanger.ac.uk), MRC clinical research training fellow,
  2. John Wain, member of faculty,
  3. E John Threlfall, professor
  1. Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge CB10 1SA
  2. Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge CB10 1SA
  3. Health Protection Agency, Centre for Infections, London NW9 5HT

    EDITOR—As Parry et al point out,12 appropriate laboratory methods are crucial in detecting clinically important quinolone resistance.

    We highlight the emergence of strains of Salmonella enterica serovar Typhi (S Typhi) that show reduced susceptibility to the fluoroquinolones but are susceptible to nalidixic acid (minimum inhibitory concentration < 16 mg/l). In a review of all 692 isolates of S Typhi sent to the Laboratory …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular